Benign Prostatic Hyperplasia (BPH): A Comprehensive Analysis of the Malaise and Summarizing Possible Management Options through Phytotherapeutic Agents

Shan Sasidharan; Kumarapillai Parameswaran Srinivasakumar; Sandeep Poddar; Amiya Bhaumik; Sreemoy Kanti Das; Hareendran Nair J

doi:10.21109/kesmas.v17i2.5887

Benign Prostatic Hyperplasia (BPH): A Comprehensive Analysis of the Malaise and Summarizing Possible Management Options through Phytotherapeutic Agents

Shan Sasidharan, Kumarapillai Parameswaran Srinivasakumar, Sandeep Poddar, Amiya Bhaumik, Sreemoy Kanti Das, Hareendran Nair J

Abstract

Benign prostatic hyperplasia (BPH) is a severe illness affecting middle-aged and geriatric male patients. This disease normally occurs at the age of 40 or above and is also associated with sexual dysfunction. Alpha-blockers and 5α-reductase inhibitors are the preferred drugs practiced to treat BPH. However, invasive surgical therapy remains the gold standard for managing the condition in the case of refractory and intricate BPH conditions. Due to the fear of sexual dysfunction and the detrimental influence on their quality of life, most patients seek to avoid synthetic drugs and surgery. For this reason, several patients turn to phytotherapy and other alternative therapies. The authors looked at the existing perceptions of epidemiology, etiology, and pathophysiology associated with BPH in this review article. In addition, this article contained basic information on the pathological roles of inflammation in BPH and various diagnoses and treatment options. It was well reported that the administration of medicinal herbs played a vital role in managing BPH. In recent years, many researchers worldwide have reported the efficiency and safety of phytochemicals in managing numerous pathological disorders in-vivo and in-vitro conditions and the prevention of illness.

Keywords

benign prostate hyperplasia, etiology, pathogenesis, pathophysiology, phytotherapy

Full Text:

PDF

References

1. Unnikrishnan R, Almassi N, Fareed K. Benign prostatic hyperplasia: evaluation and medical management in primary care. Cleve Clin J Med. 2017; 84 (1): 53-64.

2. Homma Y, Gotoh M, Yokoyama O, et al. Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol. 2011; 18 (11): 741-56.

3. Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019; 65 (5): 458-64.

4. Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012; 19 (Suppl.1): 10-17.

5. Das K, Buchholz N. Benign prostate hyperplasia and nutrition. Clin Nutr ESPEN. 2019; 33: 5-11.

6. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015; 67 (6): 1099-109.

7. Matsukawa Y, Majima T, Ishida S, Funahashi Y, Kato M, Gotoh M. Useful parameters to predict the presence of detrusor overactivity in male patients with lower urinary tract symptoms. Neurourol Urodyn. 2020; 39 (5): 1394-400.

8. Fornara P, Madersbacher S, Vahlensieck W, Bracher F, Romics I, Kil P. Phytotherapy adds to the therapeutic armamentarium for the treatment of mild-to-moderate lower urinary tract symptoms in men. Urol Int. 2020; 104 (5-6): 333-42.

9. Aaron L, Franco OE, Hayward SW. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Urol Clin North Am. 2016; 43 (3): 279-88.

10. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. The Journal of Urology. 2005; 173 (4): 1256-61.

11. Cannarella R, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. Endocrinology of the aging prostate: current concepts. Front Endocrinol. 2021; 12: 554078.

12. Devrim E, Durak I. Is garlic a promising food for benign prostatic hyperplasia and prostate cancer? Mol Nutr Food Res. 2007; 51 (11): 1319-23.

13. Espinosa G. Nutrition and benign prostatic hyperplasia. Curr Opin Urol. 2013; 23 (1): 38-41.

14. Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumbikat P, Hayward SW. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: a review. Asian J Urol. 2020;7 (3): 191-202.

15. Nimeh T, Magnan B, Almallah YZ. Benign prostatic hyperplasia: review of modern minimally invasive surgical treatments. Semin Intervent Radiol. 2016; 33 (3): 244-50.

16. Chokkalingam AP, Yeboah ED, Demarzo A, Netto G, Yu K, Biritwum RB, et al. Prevalence of BPH and lower urinary tract symptoms in West Africans. Prostate Cancer Prostatic Dis. 2011; 15 (2): 170-6.

17. Liu TT, Thomas S, Mclean DT, Roldan-Alzate A, Hernando D, Ricke EA, Ricke WA. Prostate enlargement and altered urinary function are part of the aging process. Aging. 2019; 11 (9): 2653-69.

18. Altok M, BağcıÖ, Umul M, GüneşM, Akyüz M, Uruç F, et al. Chromosomal aberrations in benign prostatic hyperplasia patients. Investig Clin Urol. 2016; 57(1):45-9.

19. Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017; 7 (1): 7984.

20. Wen S, Chang HC, Tian J, Shang Z, Niu Y, Chang C. Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. Am J Pathol. 2015; 185 (2): 293–301.

21. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011; 82 (4-5): 184–99.

22. Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 2013; 23 (1): 5–10.

23. Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU International. 2013; 112 (4): 432-41.

24. Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, Tubaro A, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU International. 2015; 115 (1): 24-31.

25. Choo MS, Han JH, Shin TY, Ko K, Lee WK, Cho ST, et al. Alcohol, smoking, physical activity, protein, and lower urinary tract symptoms: prospective longitudinal cohort. Int Neurourol J. 2015; 19 (3): 197–206.

26. Lacouture A, Lafront C, Peillex C, Pelletier M, Audet-Walsh É. Impacts of endocrine-disrupting chemicals on prostate function and cancer. Environ Res. 2022; 204 (Pt B): 112085.

27. Zhang L, Wang Y, Qin Z, Gao X, Xing Q, Li R, et al. Correlation between prostatitis, benign prostatic hyperplasia and prostate cancer: a systematic review and meta-analysis. J Cancer. 2020; 11 (1): 177-89.

28. Shah A, Shah AA, K N, Lobo R. Mechanistic targets for BPH and prostate cancer-a review. Rev Environ Health. 2020; 36 (2): 261-70.

29. Dai X, Fang X, Ma Y, Xianyu J. Benign prostatic hyperplasia and the risk of prostate cancer and bladder cancer: a meta-analysis of observational studies. Medicine. 2016; 95 (18): 3493.

30. Orsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2013; 10: 49–54.

31. Bishop FL, Rea A, Lewith H, Chan YK, Saville J, et al. Complementary medicine use by men with prostate cancer: a systematic review of prevalence studies. Prostate Cancer Prostatic Dis. 2011; 14: 1-13.

32. Nyamai DW, Mawia AM, Wambua FK, Njoroge A, Matheri F, et al. Phytochemical profile of prunus Africana stem bark from Kenya. J Pharmacogn Nat Prod. 2015; 1: 110.

33. Russo GI, Scandura C, Di Mauro M, Cacciamani G, Albersen M, Hatzichristodoulou G, et al. Clinical efficacy of serenoa repens versus placebo versus alpha-blockers for the treatment of lower urinary tract symptoms/benign prostatic enlargement: a systematic review and network meta-analysis of randomized placebo-controlled clinical trials. Eur Urol Focus. 2021; 7 (2): 420-31.

34. Paterniti I, Campolo M, Cordaro M, Siracusa R, Filippone A, Esposito E, Cuzzocrea S. Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH). Inflamm Res. 2018; 67 (7): 617-26.

35. Scaglione F, Lucini V, Pannacci M, Dugnani S, Leone C. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur Rev Med Pharmacol Sci. 2012 May 1; 16 (5): 569-74.

36. Leisegang K, Jimenez M, Durairajanayagam D, Finelli R, Majzoub A, Henkel R, et al. A systematic review of herbal medicine in the clinical treatment of benign prostatic hyperplasia. Phytomedicine Plus. 2022; 2 (1): 100153.

37. Kwon Y. Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia. Food Sci Biotechnol. 2019; 28 (6): 1599-606.

38. Latil A, Pétrissans MT, Rouquet J, Robert G, de la Taille A. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. The Prostate. 2015; 75 (16): 1857-67.

39. Sudeep HV, Venkatakrishna K, Amrutharaj B, Anitha, Shyamprasad K. A phytosterol-enriched saw palmetto supercritical CO2 extract ameliorates testosterone-induced benign prostatic hyperplasia by regulating the inflammatory and apoptotic proteins in a rat model. BMC Complement Altern Med. 2019; 19 (1): 270.

40. Yun JM, Lee M, Kim D, Prasad KS, Eun S, Kim OK, Lee J. Standardized saw palmetto extract directly and indirectly affects testosterone biosynthesis and spermatogenesis. J Med Food. 2021; 24 (6): 617-25.

41. Kumar DG, Deepa P, Rathi MA, Meenakshi P, Gopalakrishnan VK. Modulatory effects of Crataevanurvala bark against testosterone and N-methyl-N-nitrosourea-induced oxidative damage in prostate of male albino rats. Pharmacogn Mag. 2012; 8 (32): 285-91.

42. Shrivastava A, Gupta VB. Various treatment options for benign prostatic hyperplasia: a current update. J Midlife Health. 2012; 3 (1): 10-9.

43. Sridhar N, Venkataraman S, Mishra M, Ravikumar R, Jeeva SKE. Anti-nephrolithiatic effect of Crataeva magna lour. Dc. root on ethylene glycol induced lithiasis. Int J Pharm Ind Res 2011; 1 (2): 135-7.

44. Chhatre S, Nesari T, Somani G, Kanchan D, Sathaye S. Phytopharmacological overview of Tribulus terrestris. Pharmacogn Rev. 2014; 8 (15): 45-51.

45. Kaushik J, Tandon S, Bhardwaj R, Kaur T, Singla SK, Kumar J, Tandon C. Delving into the antiurolithiatic potential of tribulus terrestris extract through -in vivo efficacy and preclinical safety investigations in wistar Rats. Sci Rep. 2019; 9 (1): 15969.

46. Oh JS, Baik SH, Ahn EK, Jeong W and Hong SS: Anti-inflammatory activity of Tribulus terrestrisin raw 264.7 Cells. J Immunol. 2012; 188 (1) 54.2.

47. Soleimanpour S, Sedighinia FS, Safipour Afshar A, Zarif R, Ghazvini K. Antibacterial activity of Tribulus terrestris and its synergistic effect with Capsella bursa-pastoris and Glycyrrhiza glabra against oral pathogens: an in-vitro study. Avicenna J Phytomed. 2015; 5 (3): 210-7.

48. Vyas AB, Desai NY, Patel PK, Joshi SV, Shah DR. Effect of Boerhaavia diffusa in experimental prostatic hyperplasia in rats. Indian J Pharmac. 2013; 45 (3): 264-69.

49. Lesjak M, Beara I, Simin N, Pinta´cD,Majki´c T, BekvalacK, et al. Antioxidant and anti-inflammatory activities of Quercetin and its derivatives. J Funct Foods. 2018; 40: 68–75.

50. Gardi C, Bauerova K, Stringa B, Kuncirova V, Slovak L, Ponist S, et al. Quercetin reduced inflammation and increased antioxidant defense in rat adjuvant arthritis. Arch Biochem Biophys. 2015; 583: 150–7.

51. Hashemzaei M, Delarami Far A, Yari A, Heravi RE, Tabrizian K, Taghdisi SM, et al. Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo. Oncol Rep. 2017; 38 (2): 819–28.

52. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999; 54 (6): 960-3.

53. Ghorbanibirgani A. Efficacy of quercetin in treatment of benign prostatic hyperplasia in a double-blind randomized clinical trial in Iran 2011. Contraception. 2012; 85 (3): 321.

54. Morgia G, Privitera S. Phytotherapy in benign prostatic hyperplasia. In Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. Cambridge: Academic Press; 2018: 135-75.

55. Damiano R, Cai T, Fornara P, Franzese CA, Leonardi R, Mirone V. The role of Cucurbita pepo in the management of patients affected by lower urinary tract symptoms due to benign prostatic hyperplasia: a narrative review. Arch Ital Urol Androl. 2016; 88 (2): 136–43.

56. Vahlensieck W, Theurer C, Pfitzer E, Patz B, Banik N, Engelmann U. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int. 2015; 94 (3): 286-95.

57. Ilic D, Misso M. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas. 2012; 72 (4): 269-76.

58. Ulbricht CE. An evidence-based systematic review of beta-sitosterol, sitosterol (22,23- dihydrostigmasterol, 24-ethylcholesterol) by the natural standard research collaboration. J Diet Suppl. 2016; 13 (1): 35-92.

DOI: http://dx.doi.org/10.21109/kesmas.v17i2.5887